Technetium (99mTc) mertiatide

Technetium (99mTc) mertiatide is a radiopharmaceutical medication used in nuclear medicine to image the kidneys.[1] It is a renal imaging agent that is given by intravenous injection.[1]

Technetium (99mTc) mertiatide
Clinical data
Trade namesTechnescan Mag3
License data
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
3D model (JSmol)
  • C(C(=NCC(=O)[O-])[O-])N=C(CN=C(C[S-])[O-])[O-].O=[99Tc+3].[Na+].[Na+]
  • InChI=1S/C8H13N3O5S.2Na.O.Tc/c12-5(2-10-7(14)4-17)9-1-6(13)11-3-8(15)16;;;;/h17H,1-4H2,(H,9,12)(H,10,14)(H,11,13)(H,15,16);;;;/q;2*+1;;+3/p-5/i;;;;1+1
  • Key:JVYYEQVAPXSUSY-RCUQKECRSA-I

It was approved for medical use in the United States in June 1990.[2]

Medical uses

edit

Technetium (99mTc) mertiatide is indicated for use in the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstruction, and calculi.[1]

Chemistry

edit

The active ingredient, betiatide, is reconstituted with sodium pertechnetate 99mTc injection to form technetium (99mTc) mertiatide.[1]

References

edit
  1. ^ a b c d e "Technescan Mag3- technescan tc 99m mertiatide injection, powder, lyophilized, for solution". DailyMed. 13 December 2022. Archived from the original on 2 February 2023. Retrieved 1 February 2023.
  2. ^ "Technescan Mag3: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 13 December 2022. Retrieved 1 February 2023.